CStone Pharmaceuticals (2616) Price & Analysis

Compare

2 Followers

2616 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$0.81 - HK$3.89

Previous CloseN/A

Volume1.16M

Average Volume (3M)8.12M

Market Cap

HK$2.80B

Enterprise ValueHK$939.19M

Total Cash (Recent Filing)¥1.66B

Total Debt (Recent Filing)¥1.41M

Price to Earnings (P/E)―

Beta1.36

Next Earnings

Aug 21, 2025

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding1,364,380,600

10 Day Avg. Volume10,407,199

30 Day Avg. Volume8,121,300

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)8.23

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

---

CStone Pharmaceuticals News

PremiumCompany Announcements

CStone Pharmaceuticals Grants RSUs and Share Options to Key Personnel

1h ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals Completes Successful Share Placement

1d ago

2616

PremiumCompany Announcements

CStone CEO Increases Shareholding, Signaling Confidence in Company’s Future

2d ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals Announces HK$234.64 Million Share Placement

10d ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals Reports 2024 Financial Results with Reduced Losses

15d ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals to Present Innovative Cancer Therapies at AACR 2025

17d ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals Seeks EMA Approval for Sugemalimab in Stage III NSCLC

19d ago

2616

PremiumCompany Announcements

CStone Pharmaceuticals Schedules Board Meeting to Approve 2024 Annual Results

25d ago

2616

See All HK:2616 News

---

Financials

Quarterly

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.37%

Mutual Funds

― Other Institutional Investors

99.62% Public Companies and

Individual Investors

Detailed Ownership Overview >

2616 FAQ

What was CStone Pharmaceuticals’s price range in the past 12 months?

CStone Pharmaceuticals lowest stock price was HK$0.81 and its highest was HK$3.89 in the past 12 months.

What is CStone Pharmaceuticals’s market cap?

CStone Pharmaceuticals’s market cap is HK$2.80B.

When is CStone Pharmaceuticals’s upcoming earnings report date?

CStone Pharmaceuticals’s upcoming earnings report date is Aug 21, 2025 which is in 132 days.

How were CStone Pharmaceuticals’s earnings last quarter?

CStone Pharmaceuticals released its earnings results on Mar 27, 2025. The company reported -HK$0.085 earnings per share for the quarter, missing the consensus estimate of -HK$0.032 by -HK$0.053.

Is CStone Pharmaceuticals overvalued?

According to Wall Street analysts CStone Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CStone Pharmaceuticals pay dividends?

CStone Pharmaceuticals does not currently pay dividends.

What is CStone Pharmaceuticals’s EPS estimate?

CStone Pharmaceuticals’s EPS estimate is -0.11.

How many shares outstanding does CStone Pharmaceuticals have?

CStone Pharmaceuticals has 1,364,380,600 shares outstanding.

What happened to CStone Pharmaceuticals’s price movement after its last earnings report?

CStone Pharmaceuticals reported an EPS of -HK$0.085 in its last earnings report, missing expectations of -HK$0.032. Following the earnings report the stock price went up 2.041%.

Which hedge fund is a major shareholder of CStone Pharmaceuticals?

Currently, no hedge funds are holding shares in HK:2616

---

CStone Pharmaceuticals Stock Smart Score

Outperform

News Sentiment

Neutral

Bullish news 59%
Bearish news 50%

Technicals

Fundamentals

Return on Equity

-22.23%

Trailing 12-Months

Asset Growth

-18.96%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CStone Pharmaceuticals

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.

---

2616 Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2023","6":"Jul<br/>2023","9":"Oct<br/>2023","12":"Dec<br/>2023","25":"Dec<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.22,2.0492307692307694,1.8784615384615386,1.7076923076923078,1.536923076923077,1.3661538461538463,1.1953846153846155,1.0246153846153847,0.8538461538461539,0.6830769230769231,0.5123076923076924,0.34153846153846157,0.17076923076923078,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.63,"date":1672531200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5.09,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.11,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.55,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.21,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.8,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.49,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.5,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.23,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.85,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.12,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1701388800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >